Publication: Biomarkers Have Higher Diagnostic and Prognostic Potential Than Other Tools, page-26

Dentie, Right on ! The Q is, put another way, can Maria (with our incumbent Board) see either Evolis or Midkine through to profitability, in one form or another, with some return on our investments, in the lifetime of our cohort of hitherto true believers?

Despite progress after progress, year after year, the prima facie inability of CDY to deliver remains. This is reflected in the share price stagnant for >a decade. At the least, we should have been given enough information
to have a higher rational level of confidence (other than blind faith) in the direction of the company.

In many respects we have little idea of the business plans, timeline or any real progress. The charts Maria has presented at past AGMs with projections several years out have long since passed, with no explanation on why targets were not met. The only fact we have is a lower sp.

As you know from previous posts, Vista Partners gave up on its analyst coverage of CDY > 5 years ago on account of its assessment of CDY's inability to ever deliver. There is no evidence that anything has changed.

Shareholder disquiet, and less apathy or unconditional support as often seen here, may resonate to spur Maria (and the incumbent Board) to better things.